Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited - pharma in Navi Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U24233MH2014PTC258452 Incorporated 30 September 2014 ROC Mumbai HQ Navi Mumbai, Maharashtra, India
Active Private Limited Company pharma MSME · Small
Data last updated
Revenue · FY 2025
₹18.67 Cr
▲ 47% YoY
Net loss · FY 2025
₹5.68 Cr
Net margin -30.4%
EBITDA · FY 2025
-₹3.58 Cr
EBITDA margin -19.2%
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹17.69 Cr
Issued & subscribed
Open charges
₹17.38 Cr
Secured borrowings
Company age
12 yrs
Est. 2014
Employees · EPFO
184
Provident fund records

About Gpax Pharmaceuticals Private Limited

Data last updated:

Gpax Pharmaceuticals Private Limited is a private limited company based in Navi Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 30 September 2014 and has been in existence for over 12 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24233MH2014PTC258452. Its GSTIN is 26AAFCC7964F1ZG (Daman & Diu). The company holds 3 GST registrations, of which 1 is active.

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹17.69 Cr. It was formerly known as Celogen Generics Private Limited. It is led by directors including Anuj Somchand Bhagwanji Shah and Amit Rajan.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Off B – 106 Techno City Pl X – 4/1 X – 4/2 Ttc Area MIDC Mahape, Navi Mumbai, Maharashtra, India – 400701.

As per the financials filed for FY 2025, the company reported a revenue of ₹18.67 Cr, a growth of 47% compared to the previous year. For the same year it recorded a net loss of ₹5.68 Cr (net margin -30.4%) and EBITDA of -₹3.58 Cr (EBITDA margin -19.2%). Revenue has grown at a compounded annual rate (CAGR) of 10% over three years and 11% over five years.

The company has about 184 employees on its provident fund (EPFO) records.

As per MCA filings, the company has open charges of ₹17.38 Cr on record. Court records list 9 cases involving the company, including 9 filed against it; 3 cases are pending. The company has 6 deals on record (2 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹7.5 Cr; the latest was in March 2017. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Sunwin Healthcare Private Limited with revenue of ₹18.79 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 97 overdue payments to 7 micro and small suppliers.

Gpax Pharmaceuticals Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DD-01-0001109). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website celogenpharma.com.

Company Details of Gpax Pharmaceuticals Private Limited
CIN U24233MH2014PTC258452
Registration Number 258452
Incorporation Date 30 September 2014
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DD-01-0001109
Key People
Anuj Somchand Bhagwanji Shah Director Amit Rajan Director Vikash Naresh Shah Director

Recognitions & Rankings of Gpax Pharmaceuticals

MSME (Udyam registered) Ministry of MSME
Category
Small (2023-24)
Udyam number
UDYAM-DD-01-0001109
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    celogenpharma.com
  • Social Media
    Locked
  • Registered Address
    Off B – 106 Techno City Pl X – 4/1 X – 4/2 Ttc Area MIDC Mahape, Navi Mumbai, Maharashtra, India – 400701
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Gpax Pharmaceuticals Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Gpax Pharmaceuticals Private Limited report

Financials, compliance, directors, charges, ownership and filings for Gpax Pharmaceuticals Private Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Financials of Gpax Pharmaceuticals Private Limited FY 2025 filings available

Gpax Pharmaceuticals Private Limited reported revenue of ₹18.67 Cr (up 47% YoY) for FY 2025.

Revenue · FY 2025
₹18.67 Cr ▲ 47%
Net loss · FY 2025
₹5.68 Cr margin -30.4%
EBITDA · FY 2025
-₹3.58 Cr margin -19.2%

Compounded Annual Growth Rate (CAGR) of Gpax Pharmaceuticals Private Limited

Revenue CAGR growth
1 year
▲ 47%
3 years · compounded
▲ 10%
5 years · compounded
▲ 11%
EBITDA CAGR growth
3 years · compounded
▼ 37%
5 years · compounded
▼ 1%

Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 47% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary of Gpax Pharmaceuticals Private Limited

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations••••••••••••••••••••
Other Income••••••••••••••••••••
Total Revenue••••••••••••••••••••
Cost of Materials Consumed••••••••••••••••••••
Employee Benefit Expense••••••••••••••••••••
Finance Costs••••••••••••••••••••
Depreciation and Amortisation••••••••••••••••••••
Other Expenses••••••••••••••••••••
Total Expenses••••••••••••••••••••
EBITDA-₹3.58 Cr••••••••••••••••
Profit Before Tax••••••••••••••••••••
Tax Expense••••••••••••••••••••
Net Profit (PAT)-₹5.68 Cr••••••••••••••••
Balance Sheet
Share Capital••••••••••••••••••••
Reserves and Surplus••••••••••••••••••••
Net Worth (Total Equity)••••••••••••••••••••
Long-term Borrowings••••••••••••••••••••
Short-term Borrowings••••••••••••••••••••
Trade Payables••••••••••••••••••••
Total Liabilities••••••••••••••••••••
Fixed Assets••••••••••••••••••••
Investments••••••••••••••••••••
Inventories••••••••••••••••••••
Trade Receivables••••••••••••••••••••
Cash and Bank Balance••••••••••••••••••••
Total Assets••••••••••••••••••••

Financial Ratios of Gpax Pharmaceuticals Private Limited

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin-19.2%••••••••••••••••
Net Profit Margin-30.4%••••••••••••••••
Return on Equity (ROE)••••••••••••••••••••
Return on Capital Employed (ROCE)••••••••••••••••••••
Return on Assets (ROA)••••••••••••••••••••
Liquidity and Debt
Current Ratio••••••••••••••••••••
Quick Ratio••••••••••••••••••••
Debt-to-Equity Ratio••••••••••••••••••••
Interest Coverage Ratio••••••••••••••••••••
Efficiency and Growth
Asset Turnover••••••••••••••••••••
Receivable Days••••••••••••••••••••
Payable Days••••••••••••••••••••
Inventory Days••••••••••••••••••••
Revenue Growth••••••••••••••••••••
Net Profit Growth••••••••••••••••••••

Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Gpax Pharmaceuticals are in the company report.

Premium access

Financial statements from 2015

Earlier years and trend charts are in the company report.

  • Income statements
  • Balance sheets
  • Cash-flow statements
  • Ratios and benchmarks

Verified entity values are shown only after access is granted.

Board of Directors of Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals has 8 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Anuj Somchand Bhagwanji ShahDirector19 Jan 20242 Years 9 MonthsCurrent
Amit Rajan
Also directs: Celogen Lifescience & Technologies Private Limited, Prosfora Technologies Private Limited
Director02 Jan 201511 Years 9 MonthsCurrent
Vikash Naresh ShahDirector19 Jan 20242 Years 9 MonthsCurrent
Bharat Kakubhai Katariya
Also directs: Arkianav Private Limited
Director19 Jan 20242 Years 9 MonthsCurrent
Shailesh Kakulal KatariaDirector19 Jan 20242 Years 9 MonthsCurrent
Rabi Narayan Nayak
Also directs: Celogen Pharma Private Limited, Agam and Gem Laboratories Private Limited, Celogen Laboratories Private Limited and 2 more
Director30 Sep 201412 Years 0 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer Comparison of Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sunwin Healthcare Private Limited₹18.79 Cr (FY 2025)••••••••47.0%••••Panchkula, Haryana, India
Indu Drugs Private Limited₹18.78 Cr (FY 2025)••••••••-10.0%••••Hyderabad, Telangana, India
Gulkas Pharma Pvt Ltd₹18.78 Cr (FY 2025)••••••••21.0%••••Kalol, Gujarat, India
Anaesthetic Gases Pvt Ltd₹18.78 Cr (FY 2025)••••••••-4.0%••••Chandigarh, India
Teadus Pharma Private Limited₹18.7 Cr (FY 2024)••••••••••••Hyderabad, Telangana, India
Gpax Pharmaceuticals Private Limited this company₹18.67 Cr (FY 2025)••••••••47.0%••••Navi Mumbai, Maharashtra, India
Medilife Impex Private Limited₹18.66 Cr (FY 2025)••••••••3.0%••••Hingna, Maharashtra, India
Aakash Pharma Private Limited₹18.62 Cr (FY 2025)••••••••-4.0%••••Madurai, Tamil Nadu, India
Sai Sarvaa Biotech Private Limited₹18.57 Cr (FY 2025)••••••••3.0%••••Villupuram, Tamil Nadu, India
Cornel Pharmaceuticals Private Limited₹18.56 Cr (FY 2025)••••••••-1.0%••••Ahmedabad, Gujarat, India
One Drip Healthcare Private Limited₹18.55 Cr (FY 2024)••••••••••••Ahmedabad, Gujarat, India

Peers are the five companies nearest above and the five nearest below Gpax Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited is audited by ANRK & ASSOCIATES LLP for the financial year 2023.

NameStatusAppointment DateCessation Date
ANRK & ASSOCIATES LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Ownership and Shareholding of Gpax Pharmaceuticals Private Limited

Premium access

Shareholding and ownership data

Promoter, institutional, public and beneficial ownership figures are in the company report.

  • Ownership categories
  • Historical changes
  • Group structure
  • FII and DII holdings

Verified entity values are shown only after access is granted.

Charges & Borrowings of Gpax Pharmaceuticals Private Limited

Open charges
₹17.38 Cr
Satisfied charges
None
Breakdown by lending institutions
Nkgsb Co.Op. Bank Ltd.₹8.85 Cr
Others₹8.53 Cr
Latest charge details
DateLenderAmountStatus
31 Mar 2023Others₹2.55 CrOpen
27 Jul 2018Others₹97.5 LakhOpen
18 Jul 2018Others₹2.5 CrOpen
26 Oct 2015Nkgsb Co.Op. Bank Ltd.₹85 LakhOpen
01 Aug 2015Others₹2.5 CrOpen

Total charge records: 6 View all charges

Deals & Funding of Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited has 6 deals on record (2 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹7.5 Cr; the latest was in March 2017.

Total deals
6
Convertible or debt financings
2
Secondary share transfers
2
Rights issue
1
Funding round
1
Disclosed funding
₹7.5 Cr

Deals on record (4 of 6)

WhenDealAmountParties
Mar 2017Secondary share transferUndisclosedBuyer: an individual
Seller: 3 individuals
Jun 2015Rights issue₹1.29 CrInvestors: 4 individuals
Apr 2015Funding round₹1.25 CrInvestors: an individual
Nov 2014Secondary share transferUndisclosedBuyer: 3 individuals
Seller: an individual
Premium access

Full deal history

All 6 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 97 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 7)

SupplierAmount dueDue sinceReported on
an individual supplier••••••••••••
Icm Plastics Private Limited••••••••••••
an individual supplier••••••••••••
Times Press People Private Limited••••••••••••
an individual supplier••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 1 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited has a workforce of 184 employees as of Apr 06, 2024.

Employee count
184
Active EPFO establishments
1
Employee growth
37.31%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Recent Activity on Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals Private Limited has 14 board changes on record since 2014: 8 appointments and 6 cessations. The latest: Anuj Somchand Bhagwanji Shah was appointed as Director on 19 Jan 2024.

AGM
Gpax Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Gpax Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Anuj Somchand Bhagwanji Shah was appointed as Director.
Appointed
Bharat Kakubhai Katariya was appointed as Director.
Appointed
Shailesh Kakulal Kataria was appointed as Director.
Appointed
Vikash Naresh Shah was appointed as Director.
Charges
A charge with Others amounted to Rs. 2.55 Cr with Charge ID 100696852 was registered on 31 Mar 2023.
Ceased
Vikash Naresh Shah ceased to be Director.
Ceased
Aakash Vithalbhai Patel ceased to be Director.
Charges
A charge with Others of Rs. 0.98 Cr registered on 27 Jul 2018 with Charge ID 100258224 was modified on 10 Sep 2018.
Charges
A charge with Others amounted to Rs. 0.98 Cr with Charge ID 100258224 was registered on 27 Jul 2018.
Charges
A charge with Others of Rs. 2.50 Cr registered on 18 Jul 2018 with Charge ID 100258219 was modified on 27 Jul 2018.

14 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Gpax Pharmaceuticals Private Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Gpax Pharmaceuticals Private Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.

Total GSTINs
3
Active
1
Cancelled / inactive
2
GSTINStateStatusRegistered on
26AAFCC7964F1ZGDaman & DiuActive01 Aug 2020
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Gpax Pharmaceuticals Private Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gpax Pharmaceuticals Private Limited

Gpax Pharmaceuticals is an active private limited company based in Navi Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 30 September 2014 (12+ years old) and is registered under CIN U24233MH2014PTC258452.

Gpax Pharmaceuticals reported revenue of ₹18.67 Cr for FY 2025 (up 47% YoY).

Gpax Pharmaceuticals has 8 current directors:

Gpax Pharmaceuticals reported a net loss of ₹5.68 Cr (net margin -30.4%) and EBITDA of -₹3.58 Cr (EBITDA margin -19.2%) for FY 2025, as per its filed financial statements.

The compounded annual growth rate (CAGR) of the revenue of Gpax Pharmaceuticals is 10% over three years and 11% over five years. In the latest year (FY 2025) revenue rose 47%. CAGR is the steady yearly rate that links the first and the last year.

The GSTIN of Gpax Pharmaceuticals is 26AAFCC7964F1ZG, registered in Daman & Diu. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.

The CIN (Corporate Identification Number) of Gpax Pharmaceuticals is U24233MH2014PTC258452. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Gpax Pharmaceuticals has 9 court cases on record: 9 filed against it. 3 are pending.

Gpax Pharmaceuticals was incorporated on 30 September 2014, making it 12+ years old. It is registered with the Registrar of Companies, Mumbai.

Gpax Pharmaceuticals has 6 deals on record (2 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹7.5 Cr; the latest was in March 2017.

The peers of Gpax Pharmaceuticals by revenue are Sunwin Healthcare Private Limited, Indu Drugs Private Limited, Gulkas Pharma Pvt Ltd, Anaesthetic Gases Pvt Ltd, Teadus Pharma Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).

Anuj Somchand Bhagwanji Shah was appointed as Director on 19 Jan 2024. Bharat Kakubhai Katariya was appointed as Director on 19 Jan 2024. Shailesh Kakulal Kataria was appointed as Director on 19 Jan 2024. Gpax Pharmaceuticals has 14 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available